Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Safety and Efficacy of Nintedanib As Second-Line Therapy for Patients with Differentiated or Medullary Thyroid Cancer Progressing after First-Line Therapy. A Randomized Phase II Study of the EORTC Endocrine Task Force (protocol 1209-Entf)

Sophie Leboulleux,Ellen Kapiteijn, Saskia Litiere,Patrick Schoffski,Yann Godbert,Patrice Rodien,Barbara Jarzab,Domenico Salvatore,Sylvie Zanetta,Jaume Capdevila,Lars Bastholt,Christelle de la Fouchardiere,Yassine Lalami,Stephane Bardet,Frank Cornelis,Marek Dedecjus,Thera Links,Ward Sents,Martin Schlumberger,D. Laura Locati,Katie Newbold

Frontiers in Endocrinology（2024）

Cited 0|Views35
Key words
nintedanib,RAIR DTC,MTC,phase II trial,triple-angiokinase inhibitor
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined